Advertisement

Topics

Companies Related to "Antibe Therapeutics Receives Approval Initiate Part Phase Dose" [Most Relevant Company Matches] RSS

18:16 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Antibe Therapeutics Receives Approval Initiate Part Phase Dose" found in our extensive corporate database of over 50,000 company records.

Showing "Antibe Therapeutics Receives Approval Initiate Part Phase Dose" Companies 1–25 of 4,200+

Extremely Relevant

Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, which are chemical substances produced in the human body to regulate a range of fu...


Relevant

Tactical Therapeutics, Inc.

Tactical Therapeutics, Inc., is a privately funded company, that has developed a patented lead therapeutic, CTO, for glioblastoma and other solid cancers. Four Phase I trials in one hundred patients have been completed, and two Phase II trials are planned for rGBM and nGBM. The company is pursuing partnering, co-development and/or licensing strategies to e...

Madeira Therapeutics, LLC

Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals who serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b...


Initiate Systems

Initiate Systems enables organizations to confidently share critical data assets. Multinational corporations, healthcare organizations and government agencies rely on Initiate® software and services to deliver complete, accurate and real-time views of data spread across multiple systems, domains or databases. Initiate’s multi-domain m...

Initiate Systems, Inc.

Initiate Systems enables organizations to confidently share critical data assets. Multinational corporations, healthcare organizations and government agencies rely on Initiate® software and services to deliver complete, accurate and real-time views of data spread across multiple systems, domains or databases. Initiate’s multi-domain m...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Amarillo Biosciences Incorporated

Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease, and oral warts in HIV+ patients and chronic cough in idiopathic pulmonary fibrosis. Low-dose oral interferon is Fundamentally Different from high dose injectable interferon. In this site, we will show the fun...

BioDelivery Sciences International

We are a specialty pharmaceutical company that is exploiting its licensed and proprietary patented drug delivery technologies to develop and commercialize, either on our own or in partnerships with third parties, clinically-significant new formulations of proven therapeutics. Our development strategy focuses on the utilization of the FDA’s 505(b)(2) approval process to obtain more timely and eff...

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Geovax Labs

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining r...

Glide Pharma

Glide Pharma is a specialty pharmaceutical company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary needle-free solid dose injector, the Glide SDI(R).

Simafex

Simafex is a fine chemicals company with a worldwide presence.Founded in 1959 near La Rochelle in west France, it was part of Pierre Fabre laboratories till 1987 when it joined the French pharmaceutical group Guerbet.Years of working in close cooperation with leading pharmaceutical companies worldwide have made us a valuable partner for the synthesis of new molecules.Our main activity is concentra...

Phase One Medical, L.L.C.

Phase One Medical is a privately held medical device research and development company. The company is focused on early stage development and small part design and manufacture. For more information on Phase One Medical, L.L.C. products and services e-mail the company at info@phase-one.us.

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for Inflectr...

Synosia Therapeutics

Synosia Therapeutics is a privately owned company, which develops and intends to commercialise innovative, first or best-in-class products for unmet medical needs in neurology and psychiatry. Synosia utilises cutting-edge technologies and creative clinical study designs to de-risk its compounds before moving into larger, more extensive Phase II and Phase I...

Phase One Medical

Phase One Medical is a privately held medical device research and development company. The company is focused on early stage device development and small part design and manufacture. For more information on Phase One Medical, L.L.C. products and services e-mail the company at info@phase-one.us or visit the company’s web site at: www.phaseonemedical.co...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

ACADIA Pharmaceuticals Inc.

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is currently developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indi...

CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat der...

Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate th...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

FortuneRock (China) Ltd.

FortuneRock (China) Ltd., a privately held biotechnology and biopharmaceutical company registered in Beijing. Along with its 3 wholly owned subsidiaries, Tianjin SinoBiotech Ltd., SinoBiotech (Tianjin) Ltd. and Beijing Bio-Fortune Ltd., the group is focused on the discovery, development, and commercialization of novel, patent-protected gene-based recombina...

BioMimetic Therapeutics, Inc.

BioMimetic Therapeutics is a biotechnology company utilizing purified recombinant human platelet-derived growth factor (rhPDGF-BB) in combination with tissue specific matrices as its primary technology platform for promotion of tissue healing and regeneration. rhPDGF-BB is a synthetic form of one of the body's principal agents to stimulate and direct he...


More From BioPortfolio on "Antibe Therapeutics Receives Approval Initiate Part Phase Dose"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks